Proteome Sciences announced this week positive results from research testing several compounds as inhibitors against the candidate Alzheimer's drug target casein kinase 1 delta, or CK1δ.
The company said that it has filed intellectual property covering the results and begun optimizingthe tested compounds and testing them in an in vivo model system. Upon further lead optimization, which it hopes to complete by the middle of 2012, the company aims to license the research to a pharmaceutical firm as a drug-discovery program.
CK1δ has been shown to co-localize with the Alzheimer's protein biomarker tau, suggested that it may play some role in abnormal processing and phosphorylation of tau.
Proteome Sciences also noted that due to "increased commercial and academic interest focusing on tau protein," it has expanded its mass spec-based tau phosphorylation assay to cover ten phosphosites, including several CK1δ specific sites.
The company first launched the assay in July 2010, offering coverage of four tau phosphosites (PM 7/16/2010).